

# Contents

|  |         |
|--|---------|
| Editor's foreword .....  | page iv |
| <i>Scientific basis</i>  |         |
| Biological role of fibrinolysis JF DAVIDSON AND ISOBEL D WALKER<br>.....   | 1       |
| Biochemistry of the plasmin system D OGSTON .....  | 5       |
| Breakdown products of fibrin and fibrinogen: molecular<br>mechanisms and clinical implications PJ GAFFNEY ....         | 10      |
| Plasminogen activators: a morphologist's view AS TODD  | 18      |
| Natural inhibitors of fibrinolysis D COLLEN .....  | 24      |
| Pathophysiology of intravascular coagulation and fibrinolysis<br>AA SHARP .....  | 31      |
| <i>Therapeutic considerations</i>  |         |
| Basis of antifibrinolytic therapy CRM PRENTICE .....   | 35      |
| Clinical pharmacology of aminocaproic and tranexamic acids<br>INGA MARIE NILSSON .....                                 | 41      |
| Assessment of inhibitors with chromogenic substrates ZBIGNIEW<br>S LATALLO .....                                       | 48      |
| <i>Clinical applications</i>   |         |
| Inhibitors of fibrinolysis in the treatment of haemophilia<br>CR RIZZA .....   | 50      |
| Clinical applications of fibrinolytic inhibition in gynaecology<br>J BONNAR, J GUILLEBAUD, JM KASONDE, AND BL SHEPPARD | 55      |
| Antifibrinolytic therapy in genitourinary tract surgery LENNART<br>ANDERSSON .....                                     | 60      |
| Fibrinolysis and gastrointestinal haemorrhage L POLLER   | 63      |
| Tranexamic acid (AMCA) in aneurysmal subarachnoid<br>haemorrhage H FODSTAD .....                                       | 68      |
| Adjuvant treatment of ovarian carcinoma with tranexamic acid<br>BIRGER ÅSTEDT .....                                    | 74      |
| Future prospects for use of fibrinolysis inhibitors M VERSTRAETE<br>.....  | 77      |
| Index .....  | 81      |